Recro Pharma, Inc. Insider Trading for January 2018
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Recro Pharma, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Recro Pharma, Inc. for January 2018.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 22 2018 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Option Exercise | M | 0.00 | 5,000 | 0 | 15,000 | |
| Jan 22 2018 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Payment of Exercise | F | 8.89 | 1,575 | 14,002 | 179,231 | 180.8 K to 179.2 K (-0.87 %) |
| Jan 22 2018 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Buy | M | 0.00 | 5,000 | 0 | 180,806 | 175.8 K to 180.8 K (+2.84 %) |
| Jan 22 2018 | REPH | Recro Pharma, Inc. | McCallum Stewart | Chief Medical Offic ... | Option Exercise | M | 0.00 | 6,000 | 0 | 18,000 | |
| Jan 22 2018 | REPH | Recro Pharma, Inc. | McCallum Stewart | Chief Medical Offic ... | Payment of Exercise | F | 8.89 | 1,860 | 16,535 | 31,841 | 33.7 K to 31.8 K (-5.52 %) |
| Jan 22 2018 | REPH | Recro Pharma, Inc. | McCallum Stewart | Chief Medical Offic ... | Buy | M | 0.00 | 6,000 | 0 | 33,701 | 27.7 K to 33.7 K (+21.66 %) |
| Jan 22 2018 | REPH | Recro Pharma, Inc. | Mack Randall | Senior VP, Developm ... | Option Exercise | M | 0.00 | 3,100 | 0 | 9,300 | |
| Jan 22 2018 | REPH | Recro Pharma, Inc. | Mack Randall | Senior VP, Developm ... | Payment of Exercise | F | 8.89 | 961 | 8,543 | 33,752 | 34.7 K to 33.8 K (-2.77 %) |
| Jan 22 2018 | REPH | Recro Pharma, Inc. | Mack Randall | Senior VP, Developm ... | Buy | M | 0.00 | 3,100 | 0 | 34,713 | 31.6 K to 34.7 K (+9.81 %) |
| Jan 22 2018 | REPH | Recro Pharma, Inc. | Graff Fred | Chief Commercial Of ... | Option Exercise | M | 0.00 | 6,000 | 0 | 18,000 | |
| Jan 22 2018 | REPH | Recro Pharma, Inc. | Graff Fred | Chief Commercial Of ... | Payment of Exercise | F | 8.89 | 1,817 | 16,153 | 27,083 | 28.9 K to 27.1 K (-6.29 %) |
| Jan 22 2018 | REPH | Recro Pharma, Inc. | Graff Fred | Chief Commercial Of ... | Buy | M | 0.00 | 6,000 | 0 | 28,900 | 22.9 K to 28.9 K (+26.20 %) |
| Jan 22 2018 | REPH | Recro Pharma, Inc. | Myers Diane | Senior VP-Reg/Quali ... | Option Exercise | M | 0.00 | 2,500 | 0 | 7,500 | |
| Jan 22 2018 | REPH | Recro Pharma, Inc. | Myers Diane | Senior VP-Reg/Quali ... | Payment of Exercise | F | 8.89 | 775 | 6,890 | 18,528 | 19.3 K to 18.5 K (-4.01 %) |
| Jan 22 2018 | REPH | Recro Pharma, Inc. | Myers Diane | Senior VP-Reg/Quali ... | Buy | M | 0.00 | 2,500 | 0 | 19,303 | 16.8 K to 19.3 K (+14.88 %) |
| Jan 22 2018 | REPH | Recro Pharma, Inc. | Celano Michael | Chief Operating Off ... | Option Exercise | M | 0.00 | 6,400 | 0 | 19,200 | |
| Jan 22 2018 | REPH | Recro Pharma, Inc. | Celano Michael | Chief Operating Off ... | Payment of Exercise | F | 8.89 | 2,020 | 17,958 | 28,475 | 30.5 K to 28.5 K (-6.62 %) |
| Jan 22 2018 | REPH | Recro Pharma, Inc. | Celano Michael | Chief Operating Off ... | Buy | M | 0.00 | 6,400 | 0 | 30,495 | 24.1 K to 30.5 K (+26.56 %) |
| Jan 08 2018 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 8.84 | 1,579 | 13,956 | 726,055 | 727.6 K to 726.1 K (-0.22 %) |
| Jan 08 2018 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 8.84 | 4,732 | 41,822 | 2,172,900 | 2.2 M to 2.2 M (-0.22 %) |
| Jan 04 2018 | REPH | Recro Pharma, Inc. | Myers Diane | Senior VP-Reg/Quali ... | Option Exercise | A | 9.04 | 16,000 | 144,640 | 16,000 | |
| Jan 04 2018 | REPH | Recro Pharma, Inc. | Myers Diane | Senior VP-Reg/Quali ... | Grant | A | 0.00 | 8,000 | 0 | 16,803 | 8.8 K to 16.8 K (+90.88 %) |
| Jan 04 2018 | REPH | Recro Pharma, Inc. | Mack Randall | Senior VP, Developm ... | Option Exercise | A | 9.04 | 23,000 | 207,920 | 23,000 | |
| Jan 04 2018 | REPH | Recro Pharma, Inc. | Mack Randall | Senior VP, Developm ... | Grant | A | 0.00 | 11,500 | 0 | 31,613 | 20.1 K to 31.6 K (+57.18 %) |
| Jan 04 2018 | REPH | Recro Pharma, Inc. | Mattila Jyrki | Executive VP, Busin ... | Option Exercise | A | 9.04 | 23,000 | 207,920 | 23,000 | |
| Jan 04 2018 | REPH | Recro Pharma, Inc. | Mattila Jyrki | Executive VP, Busin ... | Grant | A | 0.00 | 11,500 | 0 | 11,500 | 0 to 11.5 K |
| Jan 04 2018 | REPH | Recro Pharma, Inc. | McCallum Stewart | Chief Medical Offic ... | Option Exercise | A | 9.04 | 32,200 | 291,088 | 32,200 | |
| Jan 04 2018 | REPH | Recro Pharma, Inc. | McCallum Stewart | Chief Medical Offic ... | Grant | A | 0.00 | 16,100 | 0 | 27,701 | 11.6 K to 27.7 K (+138.78 %) |
| Jan 04 2018 | REPH | Recro Pharma, Inc. | Celano Michael | Chief Operating Off ... | Option Exercise | A | 9.04 | 40,000 | 361,600 | 40,000 | |
| Jan 04 2018 | REPH | Recro Pharma, Inc. | Celano Michael | Chief Operating Off ... | Grant | A | 0.00 | 20,000 | 0 | 24,095 | 4.1 K to 24.1 K (+488.40 %) |
| Jan 04 2018 | REPH | Recro Pharma, Inc. | Graff Fred | Chief Commercial Of ... | Option Exercise | A | 9.04 | 25,800 | 233,232 | 25,800 | |
| Jan 04 2018 | REPH | Recro Pharma, Inc. | Graff Fred | Chief Commercial Of ... | Grant | A | 0.00 | 12,900 | 0 | 22,900 | 10 K to 22.9 K (+129.00 %) |
| Jan 04 2018 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Option Exercise | A | 9.04 | 100,000 | 904,000 | 100,000 | |
| Jan 04 2018 | REPH | Recro Pharma, Inc. | HENWOOD GERALDINE | President and CEO | Grant | A | 0.00 | 50,000 | 0 | 175,806 | 125.8 K to 175.8 K (+39.74 %) |
| Jan 04 2018 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 8.73 | 19,863 | 173,464 | 2,177,632 | 2.2 M to 2.2 M (-0.90 %) |
| Jan 04 2018 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 9.04 | 18,947 | 171,224 | 2,197,495 | 2.2 M to 2.2 M (-0.85 %) |
| Jan 04 2018 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 8.73 | 6,635 | 57,943 | 727,634 | 734.3 K to 727.6 K (-0.90 %) |
| Jan 04 2018 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 9.04 | 6,329 | 57,195 | 734,269 | 740.6 K to 734.3 K (-0.85 %) |
| Jan 04 2018 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Option Exercise | A | 9.04 | 23,000 | 207,920 | 23,000 | |
| Jan 04 2018 | REPH | Recro Pharma, Inc. | Lake Ryan David | Chief Financial Off ... | Grant | A | 0.00 | 11,500 | 0 | 11,500 | 0 to 11.5 K |
| Jan 02 2018 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 9.19 | 4,110 | 37,791 | 740,598 | 744.7 K to 740.6 K (-0.55 %) |
| Jan 02 2018 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners (Israel) ... | 10% Owner | Sell | S | 9.44 | 1,980 | 18,690 | 744,708 | 746.7 K to 744.7 K (-0.27 %) |
| Jan 02 2018 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 9.19 | 12,305 | 113,142 | 2,216,442 | 2.2 M to 2.2 M (-0.55 %) |
| Jan 02 2018 | REPH | Recro Pharma, Inc. | SCP Vitalife Partners II LP | 10% Owner | Sell | S | 9.44 | 5,926 | 55,938 | 2,228,747 | 2.2 M to 2.2 M (-0.27 %) |